Detalles de la búsqueda
1.
The need for future coronary access following surgical or transcatheter aortic valve replacement.
Catheter Cardiovasc Interv
; 98(5): 950-956, 2021 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34227736
2.
Hot topics in interventional cardiology: Proceedings from the society for cardiovascular angiography and interventions (SCAI) 2021 think tank.
Catheter Cardiovasc Interv
; 98(5): 904-913, 2021 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34398509
3.
Hot topics in interventional cardiology: Proceedings from the society for cardiovascular angiography and interventions 2020 think tank.
Catheter Cardiovasc Interv
; 96(6): 1258-1265, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32840956
4.
Rationale and design for AMPLATZER Amulet Left Atrial Appendage Occluder IDE randomized controlled trial (Amulet IDE Trial).
Am Heart J
; 211: 45-53, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30831333
5.
Treatment of Bifurcation Lesions: Has DK Crush"ed" the Competition?
Curr Cardiol Rep
; 20(10): 101, 2018 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30173390
6.
Endocarditis following transcatheter or surgical aortic valve replacement: What's the difference?
Catheter Cardiovasc Interv
; 99(5): 1597-1598, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35476280
7.
Bioresorbable vascular scaffolds for the treatment of coronary artery disease: Clinical outcomes from randomized controlled trials.
Catheter Cardiovasc Interv
; 88(S1): 21-30, 2016 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-27797464
8.
Re-instituting a live cardiology meeting without symptomatic COVID-19 transmission.
Catheter Cardiovasc Interv
; 98(2): 295-296, 2021 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33984174
9.
Clinical outcomes in real-world patients with bifurcation lesions receiving Xience V everolimus-eluting stents: Four-year results from the Xience V USA study.
Catheter Cardiovasc Interv
; 88(1): 62-70, 2016 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-26399687
10.
The ABSORB bioresorbable vascular scaffold: A novel, fully resorbable drug-eluting stent: Current concepts and overview of clinical evidence.
Catheter Cardiovasc Interv
; 86(4): 664-77, 2015 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-26386235
11.
Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study.
Lancet
; 382(9906): 1714-22, 2013 Nov 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-24004642
12.
Clinical outcomes in real-world patients with small vessel disease treated with XIENCE V® everolimus-eluting stents: one year results from the XIENCE V® USA condition of approval post-market study.
Catheter Cardiovasc Interv
; 84(1): 7-16, 2014 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-24327421
13.
Clinical outcomes in real-world patients with acute myocardial infarction receiving XIENCE V® everolimus-eluting stents: one-year results from the XIENCE V USA study.
Catheter Cardiovasc Interv
; 82(4): E385-94, 2013 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-23172848
14.
Xience side branch access stent for treatment of bifurcation coronary disease: a review of preclinical data.
J Interv Cardiol
; 25(4): 337-43, 2012 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-22726133
15.
Sustained low clinical event rates in real-world patients receiving everolimus-eluting coronary stent system from a large, prospective, condition of approval study: 2-year clinical outcomes from the XIENCE V USA Study.
J Interv Cardiol
; 25(6): 565-75, 2012 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-22998355
16.
Performance of everolimus-eluting versus paclitaxel-eluting coronary stents in small vessels: results from the SPIRIT III and SPIRIT IV clinical trials.
J Interv Cardiol
; 24(6): 505-13, 2011 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-21919955
17.
Impact of Coronary Artery Tortuosity on Outcomes Following Stenting: A Pooled Analysis From 6 Trials.
JACC Cardiovasc Interv
; 14(9): 1009-1018, 2021 05 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-33640388
18.
Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
Circulation
; 119(5): 680-6, 2009 Feb 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-19171853
19.
Contemporary bifurcation treatment strategies: the role of currently available slotted tube stents.
Rev Cardiovasc Med
; 11 Suppl 1: S17-26, 2010.
Artículo
en Inglés
| MEDLINE | ID: mdl-20495522
20.
Clinical and angiographic outcomes with an everolimus-eluting stent in large coronary arteries: the SPIRIT III 4.0 mm registry.
Catheter Cardiovasc Interv
; 75(2): 179-86, 2010 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-19877267